Total : %
01.17.21 06:58:57AM
Ideas/Opinion. Seven Biotech Buyout And Seven To Watch
The biotechnology sector in much need of good news after two months of carnage. This morning biotech investors woke up to see merger and acquisition is back with GlaxoSmithKline Plc (GSK) buy Tesaro Inc (TSRO) for $75.00 per share or $5.1B. The deal was the second largest buyout deal this year, the first was Sanofi (SNY) buy Bioverativ Inc (BIVV) for $11.6 billion. There are a total of seven major acquisition for the biotechnology sector in 2018. The other six were Bioverativ Inc (BIVV), Juno Therapeutics Inc (JUNO), Cascadian Therapeutics Inc (CASC), AveXis Inc (AVXS), ARMO Biosciences (ARMO), and Foundation Medicine Inc (FMI).
One of the interesting notes on TESARO Inc (TSRO) buyout this year was that the stock is prone to buyout rumors. Back on November 16, 2018, the late Friday buyout rumors were it six times; the most of all stock buyout rumors. The second most buyout rumors were JUNO Therapeutics (JUNO), and it was also been bought out this year. Here is the list we keep track of buyout rumors https://www.tradersfish.com/buyout
There are many biotech stocks valuations are too low with the recent sell-off, and with great pipeline still intact, we thought these next seven biotech stocks investors should keep their eye on. Only as opinions and in no particular order.
- Biohaven Pharmaceutical Holding Company LTD (BHVN)
- Clovs Oncology Inc (CLVS)
- Global Blood Therapeutics Inc (GBT)
- Portola Pharmaceuticals Inc (PTLA)
- Puma Biotechnology Inc (PBYI)
- Viking Therapeutics Inc (VKTX)
- Vertex Pharmaceutical Inc (VRTX)
Feel free to add your ideas and opinion to the list.
Disclaimer: I (we) do not hold any long positions from the stocks mentioned above. These are ideas and opinion only. Always seek a financial advisor for your investment.
Contact us:
Twitter: @BiotechMoney18
@TradersFish
Email: JT@TradersFish.com
Support@TradersFish.com
Add Your Comment
